We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byДионисий Христов
Modified over 4 years ago
Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy Pamela Samson, MD, MPHS, Varun Puri, MD, MSCI, Clifford Robinson, MD, Craig Lockhart, MD, Danielle Carpenter, MD, Stephen Broderick, MD, Daniel Kreisel, MD, PhD, A. Sasha Krupnick, MD, G. Alexander Patterson, MD, Bryan Meyers, MD, MPH, Traves Crabtree, MD The Annals of Thoracic Surgery Volume 101, Issue 6, Pages (June 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 A CONSORT (consolidated standards of reporting trials) diagram for cT2N0 esophageal cancer patients receiving esophagectomies from as recorded in the National Cancer Data Base (NCDB). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Receiver-operating characteristics curve for predicting likelihood of pathologic upstaging in cT2N0 esophageal cancer patients receiving upfront esophagectomy. Input variables included tumor grade and presence or absence of lymphovascular invasion (blue line = ROC, green line = reference line indicating no difference). (AUC = area under the curve; CI = confidence interval.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Kaplan-Meier survival curve comparing overall survival among cT2N0 esophageal cancer patients who received upfront esophagectomy and were pathologically upstaged, versus induction therapy followed by esophagectomy patients, with any resultant pathologic stage. (Treatment and pathology status: blue line = induction therapy, any pathologic status; green line = surgery first, with upstaged pathology; blue hatch marks = induction therapy, any pathologic stage, censored; green hatch marks = surgery first, with upstaged pathology, censored.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 4 Kaplan-Meier curve comparing overall survival among cT2N0 esophageal cancer patients who were pathologically upstaged after upfront esophagectomy but did not receive adjuvant chemotherapy, versus induction therapy patients with any resultant pathologic stage after esophagectomy. In this series, 182 of 326 (55.8%) pathologically upstaged upfront esophagectomy patients did not receive adjuvant chemotherapy. (Treatment and pathologic stage: blue line = induction, any pathologic stage; green line = upfront esophagectomy, no adjuvant chemotherapy; blue hatch marks = induction, any pathologic stage, censored; green hatch marks = upfront esophagectomy, no adjuvant chemotherapy, censored.) The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Thomas W. Rice, MD, Deepak Khuntia, MD, Lisa A. Rybicki, MS, David J
Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Photodynamic Laser Therapy for Lesions in the Airway
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,
Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,
Benny Weksler, MD, Jennifer L. Sullivan, MD
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,
Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.
Joshua E. Rosen, BASc, Hari B
Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,
Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation James M. Isbell, MD, MSCI, Stephen.
Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Heart Transplantation for the Failing Fontan
Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T
© 2023 SlidePlayer.com Inc. All rights reserved.